Meeting
2016 ASCO Annual Meeting
Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer.
Authors
Sarika Jain
Northwestern University Division of Hematology/Oncology, Chicago, IL
Sarika Jain , Lauren Elizabeth Nye , Cesar Augusto Santa-Maria , Hannah Garrett , Ellen Dammrich , Amanda Williams , Lauren Bontemps , Lisa E. Flaum , Francis J. Giles , William John Gradishar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT02038010
Citation
J Clin Oncol 34, 2016 (suppl; abstr 588)
DOI
10.1200/JCO.2016.34.15_suppl.588
Abstract #
588
Poster Bd #
76
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase I study of BYL719 and trastuzumab-MCC-DM1 (T-DM1) in HER2-positive metastatic breast cancer (MBC) patients with progression on trastuzumab and taxane-based therapy.
First Author: Sarika Jain
Poster
2015 ASCO Annual Meeting
Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).
First Author: Payal Deepak Shah
Poster
2014 ASCO Annual Meeting
A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC).
First Author: Cynthia X. Ma
Poster
2014 ASCO Annual Meeting
Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: STELA trial.
First Author: Tejal Amar Patel